Worldwide Medicinal Chemistry and Drug Safety R&D, Pfizer Global Research and Development, Pfizer Inc., Groton, CT 06340, USA.
Chem Res Toxicol. 2010 Jul 19;23(7):1215-22. doi: 10.1021/tx1000865.
Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems. This process can be supported by the use of existing toxicity data and mechanistic understanding of the biological processes for related compounds. In the published literature, this information is often spread across diverse sources and can be varied and unstructured in quality and content. The current work has explored whether it is feasible to collect and use such data for the development of new SARs for the hepatotoxicity endpoint and expand upon the limited information currently available in this area. Reviews of hepatotoxicity data were used to build a structure-searchable database, which was analyzed to identify chemical classes associated with an adverse effect on the liver. Searches of the published literature were then undertaken to identify additional supporting evidence, and the resulting information was incorporated into the database. This collated information was evaluated and used to determine the scope of the SARs for each class identified. Data for over 1266 chemicals were collected, and SARs for 38 classes were developed. The SARs have been implemented as structural alerts using Derek for Windows (DfW), a knowledge-based expert system, to allow clearly supported and transparent predictions. An evaluation exercise performed using a customized DfW version 10 knowledge base demonstrated an overall concordance of 56% and specificity and sensitivity values of 73% and 46%, respectively. The approach taken demonstrates that SARs for complex endpoints can be derived from the published data for use in the in silico toxicity assessment of new compounds.
药物性肝损伤是一个主要关注点,已导致大量上市药物被撤回。对化学物质的结构-活性关系(SARs)的了解可以为在药物开发过程早期识别潜在毒性作用做出重大贡献,并有助于避免此类问题。这一过程可以通过利用现有毒性数据和相关化合物的生物学过程的机制理解来支持。在已发表的文献中,这些信息通常分散在各种来源中,其质量和内容可能存在差异且结构不完整。目前的工作探讨了是否可以收集和使用这些数据来开发新的 SARs 用于肝毒性终点,并扩展该领域当前可用的有限信息。对肝毒性数据的综述被用于构建可进行结构搜索的数据库,该数据库用于分析以确定与肝脏不良影响相关的化学类别。然后进行了对已发表文献的搜索,以寻找额外的支持证据,并将所得信息纳入数据库。对汇集的信息进行了评估,并用于确定为每个识别出的类别确定 SARs 的范围。共收集了超过 1266 种化学物质的数据,并开发了 38 个类别的 SARs。SARs 已使用基于知识的专家系统 Derek for Windows (DfW) 作为结构警报实施,以允许进行明确支持和透明的预测。使用定制的 DfW 版本 10 知识库进行的评估练习表明,总体一致性为 56%,特异性和灵敏度值分别为 73%和 46%。所采用的方法表明,可以从已发表的数据中推导出复杂终点的 SARs,以用于新化合物的计算机毒性评估。